Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacy
Номер патента: EP4384541A1
Опубликовано: 19-06-2024
Автор(ы): Marco RUELLA, Yong Gu Lee
Принадлежит: University of Pennsylvania Penn
Опубликовано: 19-06-2024
Автор(ы): Marco RUELLA, Yong Gu Lee
Принадлежит: University of Pennsylvania Penn
Реферат: The present disclosure provides modified cell(s), i.e., immune cell(s) or precursor cell(s) thereof, wherein the cell(s) are engineered to express a) a chimeric antigen receptor (CAR), and b) a variant of a B-cell lymphoma 2 (Bcl-2) family protein, wherein the variant confers resistance to a cytotoxic inhibitor of the Bcl-2 family protein. Also provided are methods and uses of the modified cells, e.g., for treating at least one sign and/or symptom of cancer. Related nucleic acids, vectors, and pharmaceutical compositions are also provided.
Modulation of bcl-2 to enhance chimeric antigen receptor cancer immunotherapy efficacy
Номер патента: US20240335539A1. Автор: Yong Gu Lee,Marco RUELLA. Владелец: University of Pennsylvania Penn. Дата публикации: 2024-10-10.